5T4, also known as trophoblast glycoprotein, is an oncofoetal antigen expressing in fetal
development and cancer but rarely in adult. The high expression of 5T4 in malignancy was
found be associated with poor clinical outcomes in ovarian, gastric and colorectal cancers.
Several antibody drug conjugates are currently under development for cancer therapy in
preclinic and clinic stages.
Previously, investigators engineered a 5T4-specific biomolecule with nanomolar binding
affinity. Radiolabeling with gallium-68 resulted in 68Ga-NOTA-H006 which showed 5T4
expression in a variety of xenograft models. Thus, the aims of current study are to evaluate
the distribution and dosimetry of this novel tracer, and to explore the diagnostic values of
68Ga-NOTA-H006 in malignant tumors.